Athira Pharma Inc [NASDAQ: ATHA] stock went on an upward path that rose over 5.61% on Monday, amounting to a one-week price increase of more than 31.23%.
Over the last 12 months, ATHA stock dropped by -61.45%. The one-year Athira Pharma Inc stock forecast points to a potential downside of -10.34. The average equity rating for ATHA stock is currently 3.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $34.81 million, with 38.17 million shares outstanding and 35.41 million shares in the current float. Compared to the average trading volume of 4.63M shares, ATHA stock reached a trading volume of 7680312 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Athira Pharma Inc [ATHA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATHA shares is $0.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATHA stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Athira Pharma Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 19, 2024. The new note on the price target was released on September 04, 2024, representing the official price target for Athira Pharma Inc stock.
The Average True Range (ATR) for Athira Pharma Inc is set at 0.08 The Price to Book ratio for the last quarter was 0.30, with the Price to Cash per share for the same quarter was set at 1.84.
ATHA Stock Performance Analysis:
Athira Pharma Inc [ATHA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.23. With this latest performance, ATHA shares gained by 50.56% in over the last four-week period, additionally sinking by -67.52% over the last 6 months – not to mention a drop of -61.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATHA stock in for the last two-week period is set at 55.41, with the RSI for the last a single of trading hit 71.09, and the three-weeks RSI is set at 43.92 for Athira Pharma Inc [ATHA]. The present Moving Average for the last 50 days of trading for this stock 0.7926, while it was recorded at 0.5214 for the last single week of trading, and 2.3261 for the last 200 days.
Insight into Athira Pharma Inc Fundamentals:
Athira Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.97 and a Current Ratio set at 3.97.
Athira Pharma Inc [ATHA] Institutonal Ownership Details
There are presently around $64.34%, or 65.62%% of ATHA stock, in the hands of institutional investors. The top three institutional holders of ATHA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 5.4 million shares, which is approximately 14.099%. BAKER BROS. ADVISORS LP, holding 3.15 million shares of the stock with an approximate value of $$8.36 million in ATHA stocks shares; and BAKER BROS. ADVISORS LP, currently with $$4.33 million in ATHA stock with ownership which is approximately 4.265%.
